Business Wire

NY-DILIGENT

Share
Diligent Research Reveals Massive Gaps in How Diversity is Defined and Represented on Corporate Boards Globally

While progress has been made in driving gender diversity on corporate boards, there are still massive gaps in how diversity is defined and represented on boards around the world, according to Diligent, the global leader in modern governance providing SaaS solutions across governance, risk, compliance, audit and ESG. In fact, new research – revealed at the Modern Governance Summit today, September 12, 2022 – shows that boardroom diversity by race, ethnicity, age and LGBTQ+ representation lags significantly behind gender diversity globally.

The inaugural Board Diversity Gaps: The Global Modern Leadership Report is the first ever global analysis of several major dimensions of boardroom diversity including gender, race/ethnicity and nationality, skillset and LGBTQ+ representation. Produced by Diligent, in collaboration with 22 partnering organizations around the world, the report provides a first-of-its-kind holistic view into the progression of diversity and inclusion on public and private boards worldwide.

“Diversity has risen up the boardroom agenda as organizations face increasing pressure to better reflect the diversity of their customer bases and communities, but progress has been slow and there are still many gaps when it comes to reporting on race, ethnicity and LGBTQ+ representation on boards,” said Lisa Edwards, President and COO of Diligent and board director at Colgate-Palmolive. “This report provides new, critical insights into how boardrooms worldwide are progressing against diversity goals and where there is still much work to be done.”

Among the top findings of the Modern Leadership Report:

  • Diversity by directors’ nationality, race and ethnicity lags gender diversity globally, with the majority of analyzed countries not disclosing the ethnicity of each of the directors on the board. The percentage of S&P 500 directors from underrepresented racial/ethnic groups is only 22% and has not increased since 2021. Meanwhile, the percentages for Fortune 100 and 500 boards are 17.5% and 20.6% respectively as of 2020, and 24% for the Russell 3000 as of June 2022.
  • Director appointments are far from gender parity. Only 36% of director appointments through May 2022 were female, on pace with the average for all of 2021. Female directors currently hold approximately 27% of public company board seats, up from 26% in 2021 and a four percentage point increase from 2019.
  • Female directors trend younger than their male counterparts and have shorter tenures. The average age of female directors is roughly four years younger than their male counterparts, at 60 and 63.5 respectively. Female directors also have shorter tenures than their male counterparts at 4.7 years compared with 7.6.
  • The issue of LGBTQ+ representation significantly lags behind other elements of boardroom diversity, with the U.S. being the only region analyzed that provides this data. Members of the LGBTQ+ community hold only 0.5% of board seats in the Fortune 500.
  • New expertise types are being added to the boardroom, with 35% of newly appointed board directors bringing skillset backgrounds in areas like technology, marketing, sales, HR, ESG and legal in 2022.
  • All-Male Boards Persist for Private Companies. In a review of 228 private growth-stage companies, Diligent found 58% have all-male-boards, compared with only 6% of publicly traded companies. Women hold approximately 11% of board seats on these private companies compared to 27% in public companies.

“The global picture of boardroom diversity today is varied and full of gaps, but what’s overwhelmingly clear is that gender diversity is the primary focus for boards around the world. Board diversity regarding race, ethnicity, age and LGBTQ+ representation fall woefully behind,” said Dottie Schindlinger, Executive Director of the Diligent Institute. “By better understanding the state of boardroom diversity across the globe, we’re able to increase the odds that corporate leadership opportunities will be made available to underrepresented groups.”

Like many organizations in recent years, Diligent has made concerted efforts to better understand and advocate for boardroom diversity. In 2020 Diligent launched Modern Leadership, an initiative to provide boards and senior leaders with the research, insights, partnerships and technology they need to further catalyze diversity in their organizations. This includes the Diligent Director Network — the largest and most diverse community of board-ready executives globally.

Read the full report here: https://www.diligent.com/board-diversity-gaps/

About the Report

The Modern Leadership Report is authored by Diligent Institute, the research arm and think tank of Diligent. Using a combination of quantitative data from company filings, surveys of corporate board members, practitioner insights and director interview, the report aims to provide a more holistic story about the progression of diversity and inclusion on public and private companies worldwide across the United States, Latin America, Europe, Asia and Australia.

The report includes contributions from twenty-two external partner organizations including the Alliance for Board Diversity (ABD), Ascend, Better Boards Initiative, BoardReady, The Center of Excellence for Sustainable Environment and Social Inclusion (COE-SESI), Corporate Board Member, California Partners Project, the Director Diversity Initiative at University of North Carolina, the ESADE Centre for Corporate Governance, European Women on Boards, Hawkamah, Human Resource Governance Leaders (HRGL), INCAE, the Institute of Directors in India, Institut Luxembourgeois des Administrateurs (ILA), the Latino Corporate Directors Association (LCDA), Out Leadership and the OutQUORUM Initiative for LGBTQ+ Board Diversity, Spencer Stuart, the University of Lagos, WTW and Women Business Collaborative. Diligent ESG business unit also partnered on the report providing data and commentary to the report.

About Diligent

Diligent is the global leader in modern governance, providing SaaS solutions across governance, risk, compliance, audit and ESG. Serving more than 1 million users from over 25,000 customers around the world, we empower transformational leaders with software, insights and confidence to drive greater impact and lead with purpose. Learn more at diligent.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005205/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lone Star Announces Sale of SPX FLOW to ITT Inc.5.12.2025 13:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund XI, LP of a definitive agreement to sell SPX FLOW, Inc. (“SPX FLOW”), a leading provider of highly engineered equipment and process technologies for attractive end markets including industrial, health and nutrition, to ITT Inc. (NYSE: ITT) for $4.775 billion in cash and shares of common stock. Based in Charlotte, N.C., SPX FLOW focuses on process technologies delivering mixing, blending, fluid handling, separation, thermal heat transfer and other solutions integral to industrial, health and nutrition markets. The company has operations in more than 25 countries and sales in more than 140 countries. In partnership with Lone Star, SPX FLOW has focused on improving its sales execution and operating platform, while ensuring high quality and innovative product development. The management team has improved the company’s commercial organization and executed growth initiatives to build its presence in e

AmTrust Financial Services and Blackstone Credit & Insurance Close Strategic Transaction and Launch Newly Formed Multinational MGACompany Named ANV Group Holdings Ltd.5.12.2025 13:00:00 CET | Press release

Strategic Transaction Unlocks Value for AmTrust and Positions ANV Group Holdings for Accelerated GrowthFormer AmTrust President Adam Karkowsky Leading ANV Group Holdings as Chairman and CEO AmTrust Financial Services, Inc. (“AmTrust” or the “Company”), a global specialty property casualty insurer, and Blackstone Credit & Insurance (“BXCI”), today announced the closing of a strategic transaction under which AmTrust and funds managed by BXCI have partnered to spin-off certain of AmTrust’s Managing General Agencies (“MGAs”) and fee-based businesses in the U.S., United Kingdom, and Continental Europe, into ANV Group Holdings Ltd. (“ANV”), a newly formed independent company, following receipt of regulatory approvals. AmTrust and ANV have entered into a ten-year capacity agreement through which AmTrust will remain the underwriter for the existing books of business offered through the MGAs. As previously announced on September 15, 2025, the agreement includes seven AmTrust subsidiaries: ANV S

Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release

Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its

Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release

4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f

IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye